Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Other Gross PP&E Adjustments (2016 - 2025)

Neurocrine Biosciences' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at -$247.3 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 22.79% year-over-year to -$247.3 million; the TTM value through Dec 2025 reached -$247.3 million, up 22.79%, while the annual FY2025 figure was -$247.3 million, 22.79% up from the prior year.
  • Other Gross PP&E Adjustments reached -$247.3 million in Q4 2025 per NBIX's latest filing, up from -$468.9 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $37.9 million in Q4 2022 to a low of -$502.2 million in Q1 2025.
  • Average Other Gross PP&E Adjustments over 5 years is -$182.1 million, with a median of -$97.4 million recorded in 2021.
  • Peak YoY movement for Other Gross PP&E Adjustments: soared 280.0% in 2021, then plummeted 608.63% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $13.3 million in 2021, then soared by 184.96% to $37.9 million in 2022, then crashed by 219.26% to -$45.2 million in 2023, then tumbled by 608.63% to -$320.3 million in 2024, then increased by 22.79% to -$247.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Other Gross PP&E Adjustments are -$247.3 million (Q4 2025), -$468.9 million (Q3 2025), and -$492.3 million (Q2 2025).